18 research outputs found
Recommended from our members
Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein.
Accumulation and aggregation of alpha-synuclein in cortical and hippocampal areas is a pathological sign for dementia with Lewy bodies (DLB) and Parkinson's disease with dementia. However the mechanisms of alpha-synuclein triggered cellular dysfunction leading to the development of memory impairment is not clear. We have created a mouse model of DLB, where aggregation-prone human truncated (120 amino acid) alpha-synuclein is expressed in forebrain areas under the calcium/calmodulin-dependent protein kinase II alpha (CamKII-alpha) promoter. We have observed the presence of the transgenic protein in target forebrain areas, with small granular cytoplasmic accumulation of aggregated alpha-synuclein. This was associated with a progressive deficit in cortical-hippocampal memory tests including the Barnes maze and novel object recognition. This data suggests that low levels of aggregation prone alpha-synuclein are sufficient to induce memory deficits in mice and that forebrain regions associated with cognitive function may have an increased sensitivity to the truncated toxic form of alpha-synuclein.This work was performed with funds obtained from Alzheimerās
Research UK (grants ART-SRF2010-1, ART-PPG2009B-1).This is the accepted manuscript. The final version is available from Elsevier at http://www.sciencedirect.com/science/article/pii/S001448861400363X
Increased brain histamine H(3 )receptor expression during hibernation in golden-mantled ground squirrels
BACKGROUND: Hibernation is a state of extremely reduced physiological functions and a deep depression of CNS activity. We have previously shown that the histamine levels increase in the brain during hibernation, as does the ratio between histamine and its first metabolite, suggesting increased histamine turnover during this state. The inhibitory histamine H(3 )receptor has both auto- and heteroreceptor function, rendering it the most likely histamine receptor to be involved in regulating the activity of histamine as well as other neurotransmitters during hibernation. In view of accumulating evidence that there is a global depression of transcription and translation during hibernation, of all but a few proteins that are important for this physiological condition, we reasoned that an increase in histamine H(3 )receptor expression would clearly indicate an important hibernation-related function for the receptor. RESULTS: In this study we show, using in situ hybridization, that histamine H(3 )receptor mRNA increases in the cortex, caudate nucleus and putamen during hibernation, an increase that is accompanied by elevated receptor binding in the cerebral cortex, globus pallidus and substantia nigra. These results indicate that there is a hibernation-related increase in H(3 )receptor expression in cortical neurons and in striatopallidal and striatonigral GABAergic neurons. GTP-Ī³-S binding autoradiography shows that the H(3 )receptors in the globus pallidus and substantia nigra can be stimulated by histamine throughout the hibernation cycle, suggesting that they are functionally active during hibernation. CONCLUSIONS: These results show that the histamine H(3 )receptor gene is one of the few with a transcript that increases during hibernation, indicating an important role for the receptor in regulating this state. Moreover, the receptor is functionally active in the basal ganglia, suggesting a function for it in regulating e.g. dopaminergic transmission during hibernation
CSP alpha reduces aggregates and rescues striatal dopamine release in alpha-synuclein transgenic mice
alpha-Synuclein aggregation at the synapse is an early event in Parkinson's disease and is associated with impaired striatal synaptic function and dopaminergic neuronal death. The cysteine string protein (CSP alpha) and alpha-synuclein have partially overlapping roles in maintaining synaptic function and mutations in each cause neurodegenerative diseases. CSP alpha is a member of the DNAJ/HSP40 family of co-chaperones and like alpha-synuclein, chaperones the SNARE complex assembly and controls neurotransmitter release. alpha-Synuclein can rescue neurodegeneration in CSP alpha KO mice. However, whether alpha-synuclein aggregation alters CSP alpha expression and function is unknown. Here we show that alpha-synuclein aggregation at the synapse is associated with a decrease in synaptic CSP alpha and a reduction in the complexes that CSP alpha forms with HSC70 and STG alpha. We further show that viral delivery of CSP alpha rescues in uitro the impaired vesicle recycling in PC12 cells with alpha-synuclein aggregates and in uiuo reduces synaptic alpha-synuclein aggregates increasing monomeric alpha-synuclein and restoring normal dopamine release in 1-120h alpha Syn mice. These novel findings reveal a mechanism by which alpha-synuclein aggregation alters CSP alpha at the synapse, and show that CSP alpha rescues alpha-synuclein aggregation-related phenotype in 1-120h alpha Syn mice similar to the effect of alpha-synuclein in CSP alpha KO mice. These results implicate CSP alpha as a potential therapeutic target for the treatment of earlystage Parkinson's disease
Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice
In patients with Parkinson's disease (PD), the associated pathology follows a characteristic pattern involving inter alia the enteric nervous system (ENS), the dorsal motor nucleus of the vagus (DMV), the intermediolateral nucleus of the spinal cord and the substantia nigra, providing the basis for the neuropathological staging of the disease. Here we report that intragastrically administered rotenone, a commonly used pesticide that inhibits Complex I of the mitochondrial respiratory chain, is able to reproduce PD pathological staging as found in patients. Our results show that low doses of chronically and intragastrically administered rotenone induce alpha-synuclein accumulation in all the above-mentioned nervous system structures of wild-type mice. Moreover, we also observed inflammation and alpha-synuclein phosphorylation in the ENS and DMV. HPLC analysis showed no rotenone levels in the systemic blood or the central nervous system (detection limit [rotenone]<20 nM) and mitochondrial Complex I measurements showed no systemic Complex I inhibition after 1.5 months of treatment. These alterations are sequential, appearing only in synaptically connected nervous structures, treatment time-dependent and accompanied by inflammatory signs and motor dysfunctions. These results strongly suggest that the local effect of pesticides on the ENS might be sufficient to induce PD-like progression and to reproduce the neuroanatomical and neurochemical features of PD staging. It provides new insight into how environmental factors could trigger PD and suggests a transsynaptic mechanism by which PD might spread throughout the central nervous system
Recommended from our members
Depopulation of dense Ī±-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Parkinson's disease (PD) is characterized by the presence of Ī±-synuclein aggregates known as Lewy bodies and Lewy neurites, whose formation is linked to disease development. The causal relation between Ī±-synuclein aggregates and PD is not well understood. We generated a new transgenic mouse line (MI2) expressing human, aggregation-prone truncated 1-120 Ī±-synuclein under the control of the tyrosine hydroxylase promoter. MI2 mice exhibit progressive aggregation of Ī±-synuclein in dopaminergic neurons of the substantia nigra pars compacta and their striatal terminals. This is associated with a progressive reduction of striatal dopamine release, reduced striatal innervation and significant nigral dopaminergic nerve cell death starting from 6 and 12Ā months of age, respectively. In the MI2 mice, alterations in gait impairment can be detected by the DigiGait test from 9Ā months of age, while gross motor deficit was detected by rotarod test at 20Ā months of age when 50% of dopaminergic neurons in the substantia nigra pars compacta are lost. These changes were associated with an increase in the number and density of 20-500Ā nm Ī±-synuclein species as shown by dSTORM. Treatment with the oligomer modulator anle138b, from 9 to 12Ā months of age, restored striatal dopamine release, prevented dopaminergic cell death and gait impairment. These effects were associated with a reduction of the inner density of large Ī±-synuclein aggregates and an increase in dispersed small Ī±-synuclein species as revealed by dSTORM. The MI2 mouse model recapitulates the progressive dopaminergic deficit observed in PD, showing that early synaptic dysfunction is associated to fine behavioral motor alterations, precedes dopaminergic axonal loss and neuronal death that become associated with a more consistent motor deficit upon reaching a certain threshold. Our data also provide new mechanistic insight for the effect of anle138b's function in vivo supporting that targeting Ī±-synuclein aggregation is a promising therapeutic approach for PD
Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1ā120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice
Background: Recent clinical studies have demonstrated that dimebon, a drug originally designed and used as a non-selective antihistamine, ameliorates symptoms and delays progress of mild to moderate forms of Alzheimerās and Huntingtonās diseases. Although the mechanism of dimebon action on pathological processes in degenerating brain is elusive, results of studies carried out in cell cultures and animal models suggested that this drug might affect the process of pathological accumulation and aggregation of various proteins involved in the pathogenesis of proteinopathies. However, the effect of this drug on the pathology caused by overexpression and aggregation of alpha-synuclein, including Parkinsonās disease (PD), has not been assessed. Objective: To test if dimebon affected alpha-synuclein-induced pathology using a transgenic animal model. Methods: We studied the effects of chronic dimebon treatment on transgenic mice expressing the C-terminally truncated (1ā120) form of human alpha-synuclein in dopaminergic neurons, a mouse model that recapitulates several biochemical, histopathological and behavioral characteristics of the early stage of PD. Results: Dimebon did not improve balance and coordination of aging transgenic animals or increase the level of striatal dopamine, nor did it prevent accumulation of alpha-synuclein in cell bodies of dopaminergic neurons. Conclusion: Our observations suggest that in the studied model of alpha-synucleinopathy dimebon has very limited effect on certain pathological alterations typical of PD and related diseases
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65Ā·3 years (SD 15Ā·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0Ā·97, 95% CI 0Ā·87ā1Ā·07; p=0Ā·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1Ā·04, 95% CI 0Ā·98ā1Ā·10; p=0Ā·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0Ā·95, 95% CI 0Ā·87ā1Ā·03; p=0Ā·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication
Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra
The presynaptic protein Ī±-synuclein is central to the pathogenesis of Ī±-synucleinopathies. We show that the presence of endogenous mouse Ī±-synuclein leads to higher number of dopaminergic neurons in the substantia nigra of wild-type C57Bl/6J mice compared with C57Bl/6S mice with a spontaneous deletion of the Ī±-synuclein gene or C57Bl/6J mice with a targeted deletion of the Ī±-synuclein gene. This effect of Ī±-synuclein on dopaminergic neuron occurs during development between E10.5 and E13.5 and persists in adult life supporting the involvement of Ī±-synuclein in the development of a subset of dopaminergic neurons
Recommended from our members
CSPĪ± reduces aggregates and rescues striatal dopamine release in Ī±-synuclein transgenic mice.
Ī±-Synuclein aggregation at the synapse is an early event in Parkinson's disease and is associated with impaired striatal synaptic function and dopaminergic neuronal death. The cysteine string protein (CSPĪ±) and Ī±-synuclein have partially overlapping roles in maintaining synaptic function and mutations in each cause neurodegenerative diseases. CSPĪ± is a member of the DNAJ/HSP40 family of co-chaperones and like Ī±-synuclein, chaperones the SNARE complex assembly and controls neurotransmitter release. Ī±-Synuclein can rescue neurodegeneration in CSPĪ±KO mice. However, whether Ī±-synuclein aggregation alters CSPĪ± expression and function is unknown. Here we show that Ī±-synuclein aggregation at the synapse is associated with a decrease in synaptic CSPĪ± and a reduction in the complexes that CSPĪ± forms with HSC70 and STGa. We further show that viral delivery of CSPĪ± rescues in vitro the impaired vesicle recycling in PC12 cells with Ī±-synuclein aggregates and in vivo reduces synaptic Ī±-synuclein aggregates increasing monomeric Ī±-synuclein and restoring normal dopamine release in 1-120hĪ±Syn mice. These novel findings reveal a mechanism by which Ī±-synuclein aggregation alters CSPĪ± at the synapse, and show that CSPĪ± rescues Ī±-synuclein aggregation-related phenotype in 1-120hĪ±Syn mice similar to the effect of Ī±-synuclein in CSPĪ±KO mice. These results implicate CSPĪ± as a potential therapeutic target for the treatment of early-stage Parkinson's disease.MJ Fox Foundation, Cure PD trust, Parkinsonās UK, UK Dementia Research Institute (funded by MRC, Alz Soc., ARUK)